HOME
  • About Shionogi
    • About Shionogi
      • Message from Top Management
      • Brand Statement
      • Shionogi's Strength
      • Management Philosophy
      • Company Profile
      • Management Strategy
      • Operations
      • Compliance
      • Group Companies
      • Corporate Governance
      • Policies
      • History
  • Sustainability
    • Sustainability
      • Material Issues (Materiality)
      • Address the problem of antimicrobial resistance (AMR)
      • Environment
      • Society
      • Governance
      • Access to Healthcare
      • Stakeholder Engagement
      • Annual Report / Integrated Report / Environment Report
      • Data
      • External Evaluation
      • About United Nations Global Compact
      • Information related to infectious diseases
  • Innovation
    • Innovation
      • R&D
      • Partnering
      • Pipeline
      • IP Strategy
      • Adjuvant
      • Wastewater-based Epidemiology Surveillance Service
  • News
  • Investors
    • Investors
      • Top Message
      • Latest IR Information
      • IR Library
      • Management Policy
      • Shareholder Information
      • Individual Investors
      • Sustainability
      • Financial Highlights
      • IR Calendar
  • Contact Us
  • Careers
English
Worldwide
our medium-term business plan
[Wastewater-based Epidemiology Surveillance Service]

[Wastewater-based Epidemiology Surveillance Service]

By measuring the traces of the virus in wastewater, it is possible to assess, in an unbiased manner, the prevalence of SARS-CoV-2 infections in a community, including asymptomatic individuals who are not tested.

Drive Innovation

[Innovation]

Drive Innovation

Create innovations beyond the borders of medical / Pharmaceutical fields, unbound from existing concepts, showing every consideration for social issues

Sustainability

[Sustainability]

Grow sustainably as a drug discovery based pharmaceutical company contributing to a more vigorous society through improved healthcare

News

Jun.09, 2023 Release
Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
Jun.05, 2023 Notice
Transcript of Medium-Term Business Plan STS2030 Revision
Jun.01, 2023 Notice
Presentation Materials for Revision of the Medium-Term Business Plan STS2030
Jun.01, 2023 Release
Revision of the Medium-Term Business Plan STS2030
Jun.01, 2023 Release
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana
News

Commitment to Fight COVID-19

Shionogi's effort to fight with COVID-19

Beware of Solicitations, “Phishing” e-mails, and SNS that Fraudulently Use the Name of SHIONOGI

Site Search

Brand Statement

Building innovation platforms to shape the future of healthcare.

SHIONOGI is transforming our business model from a "drug-discovery-oriented pharmaceutical company" to a "healthcare provider" to pursue the health that people truly wish for and deliver new value to society.

more

About Shionogi

We are fully committed to achieving the goals of STS2030 and strive to realizing "SHIONOGI Group heritage" globally.

Sustainability

Shionogi's susutainability programs which toward to become a company that will be needed by stakeholders now and in the future.

Innovation

Shionogi's Innovation always comes from the passion to provide new value which meet the needs of society and customers, in the healthcare field.

Investors

Based on disclosure policy, Shionogi disclose information fairly, timely, appropriately and continuously to all stakeholders.

  • About Shionogi
  • Sustainability
  • Innovation
  • News
  • Investors
  • Terms of Service
  • Sitemap
  • Personal Information
Copyright (C) Shionogi & Co., Ltd. All Rights reserved.